ENTPD1 and Stroke: For example, NTPDase1/CD39 was shown to eliminate vascular thrombosis and inflammation (Kanthi et al., 2014; Covarrubias et al., 2016; Anyanwu et al., 2019; Yadav et al., 2019), whereas purinergic antithrombotic drugs demonstrated efficacy in lowering the likelihood of recurrent strokes and heart attacks (Burnstock, 2006).